An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Midwest Eye Institute, Carmel, Indiana

Sierra Eye Associates, Reno, Nevada

Retina Foundation of the Southwest, Dallas, Texas